NCT01231321View on ClinicalTrials.gov

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Rheumatoid Arthritis
Interventions
DRUG

adalimumab

Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.

Trial Locations (5)

115522

Site Ref # / Investigator 7417, Moscow

117513

Site Ref # / Investigator 17681, Moscow

119049

Site Ref # / Investigator 7401, Moscow

191015

Site Ref # / Investigator 18081, Saint Petersburg

420095

Site Ref # / Investigator 17682, Kazan'

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY